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Introduction
Invasive diseases caused by Streptococcus	pneumoniae 
(pneumococcus) are a major public health issue in Eu-
rope as well as worldwide. Severe diseases caused by 
pneumococci are pneumonia, meningitis and febrile 
bacteraemia; otitis media is a more common, but less 
serious manifestation of pneumococcal infection.
Pneumococcus can affect all age groups but the bigger 
burden of disease is among children, elderly and other 
vulnerable people, like those with conditions associated 
with immune deficiency.
The World Health organisation (WHo) estimated in 
2005 that 0.7-1 million children below 5 years of age 
died of pneumococcal disease. Most of those deaths 
are in the developing countries [1]. In the industrialised 
world pneumococcal meningitis still shows fatality rates 
of 5-10% (much higher in those with underlying serious 
conditions); fatality rates of pneumococcal pneumonia 
are generally age-related and can range between 10 and 
30% [2].
S.	pneumoniae is showing a growing resistance to com-
monly used antibiotics. This highlights the urgent need 
for effective vaccines against pneumococcal infection.
Specific protection against capsular polysaccharide anti-
gens is needed to prevent pneumococcal infections and 
invasive disease. Pneumococcal vaccines have been de-
veloped to cover the serotypes that are most frequently 
cause of invasive disease in different age groups. 
Currently a 7-valent protein-conjugated (PCV7) and an 
unconjugated 23-valent vaccine are available world-
wide. The 23-valent is licensed for use after 2 years of 
age and is designed for use in older children and adults. 
PCV7 is licensed for use under 5 years of age and can 
be easily integrated in most of the childhood vaccination 
schedules.
PCV7 has been licensed in the US in February 2000. 
In october 2000 the Advisory Committee for Im-
munisation Practice (ACIP) recommended the use of 
PCV7 for all American children aged 2-23 months 
and for those aged 24-59 months that are at higher 
risk of pneumococcal invasive disease [3]. The first 
evaluation carried out during the following years in-
dicated substantial declines in invasive pneumococcal 
disease (IPD) in children and adults compared with 
pre-vaccine years; surprisingly the vaccine prevented 
more than twice as many IPD cases in 2003 through 
indirect effects on pneumococcal transmission (i.e., 
herd immunity) than through its direct effect of pro-
tecting vaccinated children [4]. 
Epidemiology of S. pneumoniae in Europe: 
what we do, what we don’t and what we 
should know
Taking an informed decision on introduction of a new 
vaccine is always a challenge. In the case of S.	 pneu-
moniae this issue is even more complex because the 
driver of the decision are – in addition to the cost of 
the vaccine – some epidemiological considerations that 
are not trivial. First of all, assessment of the burden of 
disease is complex: 1) S.	 pneumoniae causes a large 
spectrum of diseases from otitis media to septicaemia; 
2) invasive diseases like meningitis and septicaemia can 
be caused by many different bacteria other than pneu-
mococcus and only microbiological issues can define 
the etiological diagnosis; 3) in many medical settings 
it is not routinely identified the serotype and then often 
it is not possible to ascertain if it is a vaccine serotype 
(VT) or not; 4) the incidence of specific pneumococcal 
bacteraemia is strongly dependant by the attitude at 
routinely performing haemoculture. In addition, there 
are still many unknowns regarding the possible role of 
the vaccination in inducing changes in the ecology of 
S.	 pneumoniae. Some of these expected changes can 
be positive, like the reduction of antimicrobial resistant 
strains, but the most feared one is the strain replacement 
with non-VT. Last but not least, the herd immunity ef-
fect – well described in the US experience – is difficult 
to assess and, in particular, to measure. 
Without any doubt surveillance of IPD in the European 
Union (EU) is a critical point in the decision making 
process for defining vaccination policies. There is still 
no EU-wide surveillance system for IPD. According to 
a recent survey coordinated by the ECDC, surveillance 
systems for IPD are very heterogeneous in the EU. on 
the other hand there are also some strengths that may 
represent a basis for EU-wide surveillance. one of those 
is the presence of pneumococcal meningitis surveillance 
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in all countries; the other one is the wide availability of 
serotyping that could provide important information for 
assessing the impact of vaccination programmes. 
Nevertheless, even in absence of routine surveillance 
systems, many observational studies provided a lot of 
information on the burden of IPD in Europe. of course, 
lack of coordination and standard methodology leads 
to difficult comparability and makes impossible any 
benchmarking.
A systematic review performed in 2006 highlighted a 
huge variability of incidence levels between different 
European countries [5]. Eighteen studies conducted in 
10 different European countries were considered for the 
systematic review. Incidence values of IPD in children 
below 2 years of age ranged from 11.30 to 37.80 per 
100,000; incidence rates were much higher (up to 90 
per 100,000) when included occult bacteraemia. Combi-
ning the studies altogether the incidence resulted 27.03 
per 100,000. No clear geographical pattern was shown, 
being the differences mostly attributable to different ca-
se definitions and diagnostic issues. When the Authors 
have included in the calculation only the incidence of 
pneumococcal meningitis, differences between countries 
were less evident ranging from 3.78 to 14.64; the combi-
ned value was 8.71 (95% CI 7.06 – 10.76 per 100,000). 
Those data are showing a picture substantially different 
from the US situation, where the incidence of IPD in the 
pre-vaccine era was estimated to be close to 80 cases per 
100,000 in children below 5 years of age [4]. It is hard 
to say either pneumococcal disease burden is really that 
different in the US in comparison with Europe, or it is 
more the result of surveillance artefacts, nevertheless 
such discrepancies have had an important impact on the 
decision making process in the EU.
one of the most debated issues in Europe has been 
the impact of PCV7 vaccination on the ecology of S.	
pneumoniae, fearing that the strain replacement by non-
VT could reduce the effectiveness of the vaccination 
programme.
The initial estimate, done by US CDC, was that se-
rotypes included in PCV7 accounted for 86% of bacte-
raemia and 83% of meningitis in children les than 5 
years of age. Serotype coverage of PCV7 in Europe 
has been estimated – in the pre-vaccine era – around 
75% [5], sensitively lower than what expected in the 
American epidemiological setting. Unfortunately – also 
in this case – we cannot rely on a unique source of in-
formation and the variation between countries is pretty 
high: according to the registration file, PCV7 should 
cover between 54% and 84% of isolates from IPD in 
European children less than 2 years of age and between 
62% to 83% in children 2 to 5 years of age [6].
According to the UK surveillance system, since PCV7 
introduction in 2006 the number of reports of IPD due 
to non-VT almost doubled in children below 5 years of 
age; nevertheless the overall impact on IPD in children 
has to be considered still high because the huge reduc-
tion of cases due to VT [7]. Moreover, it is not possible 
to rule out the possibility that the increased number of 
reports might be due to surveillance artefacts linked 
to increased sensitivity of the system after the vaccine 
introduction. 
In countries where the vaccine is widely used but not 
universally administered, such as Italy, Spain and Por-
tugal, the situation is even more complex, results are 
difficult to interpret and forecast of trends are unfeasi-
ble. In a study conducted in Navarra (Spain) in 2006 the 
approach to the problem was different than surveillance 
data analysis [8]. The Authors conducted a case-con-
trol study to assess the vaccination status of children 
diagnosed with IPD. This way they assessed the effect 
of replacement at the individual level in the vaccinated 
children. The estimated effectiveness of vaccination 
with PCV7 in preventing IPD, regardless of serotype, 
was only 31%, because the vaccinated children had a 6 
times greater risk of IPD due to non-VT than did those 
who were not vaccinated. These findings are difficult to 
compare with other observations done in Spain in low-
coverage situation [9] and with other studies conducted 
in Portugal in a very similar situation [10] and any 
conclusive interpretation is not possible at the present. 
For this reason the issues of serotype replacement and 
vaccine effectiveness deserve further investigation in 
order to better understand some local dynamics related 
to different levels of vaccination coverage.
Introduction of PCV7 into European 
childhood vaccination schedules
The European Commission granted a marketing autho-
risation valid throughout the European Union for PCV7 
(Prevenar) to Wyeth Lederle Vaccines on 2 February 
2001. The marketing authorisation was renewed on 2 
February 2006.
Even though the availability of PCV7 on the European 
market followed by only few months the introduction 
of Prevenar in the US routine childhood immunisation 
schedule, nevertheless the decision on starting PCV7 
universal vaccination  has been slow and patchy in the 
EU countries (Fig. 1). 
In 2004 a European wide survey was conducted as 
part of a EU funded project on pneumococcal disease 
(Pnc-EURo). Information on pneumococcal vaccination 
policies – including both adult and children immuni-
sation – were collected by the means of a standardised 
questionnaire that was completed by 23 countries [11]. 
According to the results from that survey, in 2004 vacci-
ne was available on the market in all but 3 (Estonia, Slo-
venia and Malta) of those countries participating in the 
survey; at that time only 12 EU countries had developed 
national recommendations. Most of the countries recom-
mended PCV7 to be used in high risk groups. Universal 
childhood vaccination was started only in Luxembourg.
Findings from this survey clearly illustrated how in Eu-
rope there was already an important delay in introducing 
PCV7 vaccination in comparison with the US. In 2004 
only Luxembourg had started PCV7 universal vacci-
nation programme. on the other hand the definition of 
“risk groups” was very different, then the number of 
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recommended risk groups varied a lot from country to 
country from very limited to very extensive indications 
including children attending day-care, such as in France. 
on the other hand, at that time important evidence on 
the impact of pneumococcal childhood vaccination was 
already coming from the other side of the ocean [4], 
raising the issue of equity and access to healthcare for 
those countries – like the majority of the EU – where 
the vaccine was available on the private sector but not 
reimbursed by the health insurance scheme.
In 2006 a EU-roundup was conducted by the Eurosur-
veillance journal in 25 EU countries plus Norway, Ro-
mania and Bulgaria, that at that time had not joined yet 
the EU [12]. Results from that survey showed a slowly 
moving situation, as 9 countries – after Luxembourg 
that was the first – had started a universal vaccination 
programme: Belgium, Cyprus, Greece, France, Ger-
many, the Netherlands, Norway, UK together with some 
regions in Italy, where the national authorities recom-
mended the PCV7 but delegated the decision on its in-
troduction to the regions. In addition, 9 countries recom-
mended the PCV7 vaccination for selected risk groups. 
At that time none of the Central-Eastern European coun-
tries had introduced yet universal vaccination. 
More recently, a new EU wide survey has been con-
ducted by the European Centre for Disease Prevention 
and Control (ECDC) in collaboration with the EUVAC 
network [13]. Updated information up to the end of 2008 
have been collected in all EU countries plus Norway and 
Iceland [14]. In comparison with the situation in 2006, 
6 more countries had started a universal vaccination 
programme (or delivered recommendation for universal 
childhood vaccination) with PCV7: Austria, Denmark, 
Hungary, Ireland, Slovakia and Sweden. Some findings 
from this survey are remarkable: 
• the situation at the end of 2008 was really improved 
in comparison with the previous years;
• PCV7 is universally utilised in most of the Western 
European countries, but also some Central-Eastern 
countries started a universal vaccination program-
me;
• analysis of data on vaccine sales demonstrates that 
countries like Portugal and Spain – that did not start 
a universal vaccination programme – indeed largely 
utilise PCV7 vaccination, mostly through the private 
market [14]. 
Finally, it is important to underline that all the three 
surveys showed an extreme variability in terms of 
vaccination schedule: both number of doses and re-
commended intervals present a huge variation due to 
the need of adapting them to the basic childhood im-
munisation schedule. For this reason, the same vaccine 
product – Prevenar, that is centrally authorised through 
the EMEA – is actually used in several different ways 
in different EU countries (three or four doses schedule 
with an endless list of different time intervals).
Final considerations
Pneumococcal vaccination in children is a clear example 
of how vaccination programmes are dealt in a different 
way in the US than in Europe. 
In the US, recognising IPD in children as a public heal-
th priority has led to the development of a multivalent 
vaccine designed on the basis of the national epide-
miological situation, followed by the rapid decision 
on integrating it in the basic immunisation schedule. 
Immediately after vaccine introduction national autho-
rities were able to assess the impact of the vaccination 
programme and to highlight the main challenges for 
further improvements.
Fig. 1. introduction of pCv7 in eu + eeA/eFtA member States. 
Situation update in 2004, 2006 and 2008. Source of information 
and more details in the text.
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only one year after the introduction in the US, PCV7 
was available for the use on the EU market. Neverthe-
less decision on PCV7 introduction has been very slow, 
patchy and – after introduction – few countries put in 
place effective systems for monitoring the impact of 
vaccination programme.
one explanation can be linked to the cost of PCV7 that 
actually has been the first expensive one in the vaccines 
panorama. In some countries just adding PCV7 would 
have meant to double the overall expenses for infant 
vaccination. In addition, lack of reliable epidemiologi-
cal data prevented any assessment of cost-effectiveness 
at national or regional level. The fact that the seven 
serotypes included into the vaccine had been picked 
up according to the US epidemiology did not help the 
decision.
The availability of PCV7 on the private market only – in 
those countries without a national programme covered 
by health insurances – raises also some inequality is-
sues.
Unfortunately, the role of EU institutions have been ve-
ry weak in this field, due to several legislative constrains 
that make human vaccination a matter of almost exclu-
sive national competence. The presence of the European 
Centre for Disease Prevention and Control (ECDC) [15] 
is trying to fill a gap by the means of establishing EU-
wide surveillance systems, setting up steady discussion 
forums [16] and facilitating experience and best-practi-
ce sharing. 
Nevertheless, there is a long way to go before esta-
blishing a good platform for common vaccination poli-
cies in the EU. In the meanwhile new vaccine products 
effective against IPD are coming on the market. Maybe 
this will be an opportunity for re-discussing pneumo-
coccal vaccination policies and hopefully to agree upon 
a more harmonised European approach.
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